Which has preferable valuation & earnings, AMGN or BIIB?

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $38.10B 6.14 $7.71B $16.09 26.88 Biogen $10.03B 3.22 $1.29B $5.65 38.67

Is AMGN or BIIB more profitable?

Amgen has a net margin of 22.95% compared to Biogen's net margin of 8.32%. Amgen's return on equity of 124.14% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% Biogen 8.32% 11.18% 6.88%

Does the media prefer AMGN or BIIB?

In the previous week, Amgen had 32 more articles in the media than Biogen. MarketBeat recorded 70 mentions for Amgen and 38 mentions for Biogen. Amgen's average media sentiment score of 1.40 beat Biogen's score of 1.25 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 61 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, BIIB or DNLI?

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.22 $1.29B $5.65 38.67 Denali Therapeutics $330.53M 11.61 -$512.54M -$2.84 N/A

Does the media prefer BIIB or DNLI?

In the previous week, Biogen had 32 more articles in the media than Denali Therapeutics. MarketBeat recorded 38 mentions for Biogen and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.73 beat Biogen's score of 1.25 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, BIIB or GILD?

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.22 $1.29B $5.65 38.67 Gilead Sciences $30.46B 5.93 $8.51B -$2.67 N/A

Is BIIB or GILD more profitable?

Biogen has a net margin of 8.32% compared to Gilead Sciences' net margin of -10.64%. Biogen's return on equity of 11.18% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Gilead Sciences -10.64% -2.11% -0.75%

Does the media favor BIIB or GILD?

In the previous week, Gilead Sciences had 41 more articles in the media than Biogen. MarketBeat recorded 79 mentions for Gilead Sciences and 38 mentions for Biogen. Gilead Sciences' average media sentiment score of 1.37 beat Biogen's score of 1.25 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 66 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IONS or BIIB?

In the previous week, Biogen had 20 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 38 mentions for Biogen and 18 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.32 beat Biogen's score of 1.25 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MRNA or BIIB?

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 28.34 -$2.82B -$7.99 N/A Biogen $10.03B 3.22 $1.29B $5.65 38.67

Is MRNA or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Moderna's net margin of -141.43%. Biogen's return on equity of 11.18% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Biogen 8.32% 11.18% 6.88%

Does the media prefer MRNA or BIIB?

In the previous week, Moderna had 39 more articles in the media than Biogen. MarketBeat recorded 77 mentions for Moderna and 38 mentions for Biogen. Biogen's average media sentiment score of 1.25 beat Moderna's score of 0.42 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 33 Very Positive mention(s) 15 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 10 Very Negative mention(s) Neutral Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Biogen (BIIB) Competitors

$218.50 -3.00 (-1.35%)

As of 08/28/2026 04:00 PM Eastern

Compare

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

Should you buy Biogen stock or one of its competitors? Biogen's main competitors and comparable companies include Amgen (AMGN), Denali Therapeutics (DNLI), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biogen compare to Amgen?

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$38.10B	6.14	$7.71B	$16.09	26.88
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67

76.5% of Amgen shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Amgen has a net margin of 22.95% compared to Biogen's net margin of 8.32%. Amgen's return on equity of 124.14% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
Biogen	8.32%	11.18%	6.88%

In the previous week, Amgen had 32 more articles in the media than Biogen. MarketBeat recorded 70 mentions for Amgen and 38 mentions for Biogen. Amgen's average media sentiment score of 1.40 beat Biogen's score of 1.25 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	61 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amgen presently has a consensus price target of $380.43, indicating a potential downside of 12.02%. Biogen has a consensus price target of $227.79, indicating a potential upside of 4.25%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.39
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Amgen beats Biogen on 11 of the 16 factors compared between the two stocks.

How does Biogen compare to Denali Therapeutics?

Biogen (NASDAQ:BIIB) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Biogen currently has a consensus target price of $227.79, indicating a potential upside of 4.25%. Denali Therapeutics has a consensus target price of $35.85, indicating a potential upside of 49.36%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Biogen has a net margin of 8.32% compared to Denali Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Denali Therapeutics	N/A	-55.27%	-44.24%

In the previous week, Biogen had 32 more articles in the media than Denali Therapeutics. MarketBeat recorded 38 mentions for Biogen and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.73 beat Biogen's score of 1.25 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67
Denali Therapeutics	$330.53M	11.61	-$512.54M	-$2.84	N/A

87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Summary

Biogen beats Denali Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Biogen currently has a consensus price target of $227.79, indicating a potential upside of 4.25%. Gilead Sciences has a consensus price target of $158.04, indicating a potential upside of 8.48%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.83

87.9% of Biogen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Biogen has a net margin of 8.32% compared to Gilead Sciences' net margin of -10.64%. Biogen's return on equity of 11.18% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Gilead Sciences	-10.64%	-2.11%	-0.75%

In the previous week, Gilead Sciences had 41 more articles in the media than Biogen. MarketBeat recorded 79 mentions for Gilead Sciences and 38 mentions for Biogen. Gilead Sciences' average media sentiment score of 1.37 beat Biogen's score of 1.25 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	66 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67
Gilead Sciences	$30.46B	5.93	$8.51B	-$2.67	N/A

Summary

Gilead Sciences beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ionis Pharmaceuticals presently has a consensus target price of $94.15, indicating a potential upside of 54.22%. Biogen has a consensus target price of $227.79, indicating a potential upside of 4.25%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Biogen had 20 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 38 mentions for Biogen and 18 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.32 beat Biogen's score of 1.25 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Ionis Pharmaceuticals' net margin of -64.76%. Biogen's return on equity of 11.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	10.75	-$381.39M	-$3.46	N/A
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67

Ionis Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Summary

Biogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Biogen compare to Moderna?

Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Moderna presently has a consensus price target of $80.53, indicating a potential downside of 41.64%. Biogen has a consensus price target of $227.79, indicating a potential upside of 4.25%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.17
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	28.34	-$2.82B	-$7.99	N/A
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67

75.3% of Moderna shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Moderna had 39 more articles in the media than Biogen. MarketBeat recorded 77 mentions for Moderna and 38 mentions for Biogen. Biogen's average media sentiment score of 1.25 beat Moderna's score of 0.42 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	33 Very Positive mention(s)	15 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	10 Very Negative mention(s)	Neutral
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Moderna's net margin of -141.43%. Biogen's return on equity of 11.18% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Biogen	8.32%	11.18%	6.88%

Moderna has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Summary

Biogen beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIIB vs. The Competition

Export

Metric	Biogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.73B	$4.02B	$7.24B	$12.93B
Dividend Yield	N/A	3.60%	2.54%	10.96%
P/E Ratio	38.67	11.56	271.50	25.38
Price / Sales	3.22	1,345.95	623.92	96.47
Price / Cash	9.79	110.59	79.29	54.21
Price / Book	1.71	16.50	12.95	6.14
Net Income	$1.29B	-$22.76M	$3.46B	$347.93M
7 Day Performance	0.79%	-0.23%	-0.11%	-0.78%
1 Month Performance	4.33%	11.93%	8.32%	5.60%
1 Year Performance	65.25%	55.61%	24.70%	15.64%

Biogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIIB Biogen	3.5974 of 5 stars	$218.50 -1.4%	$227.79 +4.2%	+64.7%	$32.73B	$10.03B	38.67	7,500	Positive News Analyst Forecast
AMGN Amgen	4.271 of 5 stars	$419.38 +1.0%	$372.39 -11.2%	+51.4%	$226.73B	$38.10B	26.06	31,500	Trending News
DNLI Denali Therapeutics	3.3958 of 5 stars	$24.35 -0.2%	$35.92 +47.5%	+53.4%	$3.89B	$330.53M	N/A	430	Positive News Analyst Forecast
GILD Gilead Sciences	4.1358 of 5 stars	$138.92 +0.4%	$158.04 +13.8%	+29.4%	$172.25B	$30.46B	N/A	17,000	Trending News Insider Trade
IONS Ionis Pharmaceuticals	3.7991 of 5 stars	$58.63 +2.4%	$94.65 +61.4%	+43.2%	$9.74B	$944M	N/A	1,402	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIIB) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Summary

How does Biogen compare to Denali Therapeutics?

Summary

How does Biogen compare to Gilead Sciences?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Summary

How does Biogen compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Which has preferable valuation & earnings, AMGN or BIIB?

Do institutionals & insiders believe in AMGN or BIIB?

Which has more volatility & risk, AMGN or BIIB?

Is AMGN or BIIB more profitable?

Does the media prefer AMGN or BIIB?

Do analysts prefer AMGN or BIIB?

Summary

How does Biogen compare to Denali Therapeutics?

Do analysts prefer BIIB or DNLI?

Is BIIB or DNLI more profitable?

Does the media prefer BIIB or DNLI?

Which has stronger earnings and valuation, BIIB or DNLI?

Do institutionals and insiders believe in BIIB or DNLI?

Which has more risk and volatility, BIIB or DNLI?

Summary

How does Biogen compare to Gilead Sciences?

Do analysts recommend BIIB or GILD?

Do insiders and institutionals believe in BIIB or GILD?

Which has more volatility & risk, BIIB or GILD?

Is BIIB or GILD more profitable?

Does the media favor BIIB or GILD?

Which has higher earnings and valuation, BIIB or GILD?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Do insiders & institutionals have more ownership in IONS or BIIB?

Do analysts prefer IONS or BIIB?

Does the media refer more to IONS or BIIB?

Is IONS or BIIB more profitable?

Which has stronger valuation & earnings, IONS or BIIB?

Which has more volatility & risk, IONS or BIIB?

Summary

How does Biogen compare to Moderna?

Do analysts recommend MRNA or BIIB?

Which has higher valuation & earnings, MRNA or BIIB?

Do institutionals and insiders have more ownership in MRNA or BIIB?

Does the media prefer MRNA or BIIB?

Is MRNA or BIIB more profitable?

Which has more risk & volatility, MRNA or BIIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools